Clinical trials since 2022

Date Country Disease Title Phase Status +info
10/2023

Germany

PSA
a Prospective, Randomized, Controlled,
Open Label, Assessor-Blinded, Parallel-Group
Phase III Clinical Trial to Evaluate the Impact of
Tapering Systemic Immunosuppressive Therapy
in a Treat-to-Target Approach on Maintaining
Minimal Disease Activity in Adult Subjects with
Psoriatic Arthritis.
III/IV

Ongoing*

06/2023

Germany

Both
Safety and immunologic response of shingrix
vaccination in patients suffering from psoriasis
or psoriatic arthritis shivap.
II

Ongoing*

04/2023

Denmark

Psoriasis

An Investigator-Initiated, Phase 4, Open-Label,
Single-Arm, Single-Center Study Investigating
the Tissue-Resident Memory t-Cells
and Disease Memory in Psoriasis Skin During
Guselkumab Treatment. the Gusmem Study.
IV

Ongoing*

03/2023

Bulgaria

Czech Republic

Germany

Hungary

Spain

PSA
Vtx958 versus placebo for the treatment
of active psoriatic arthritis.
II

Ongoing*

03/2023

Poland

Psoriasis
A research study to evaluate if vtx958, a test
medicine, not yet approved for doctors to
prescribe, is safe and will help in the treatment
of psoriasis.
II

Ongoing*

01/2023

Czech Republic

Poland

Psoriasis
A study to evaluate esk-001 in patients with psoriasis.
II

Ongoing*

01/2023

France

Greece

Italy

Spain

PSA
Apremilast study in children with active oral
ulcers associated with behets disease or
juvenile psoriatic arthritis.
III

Ongoing*

11/2022

Denmark

France

Germany

Netherlands

Poland

Spain

PSA
Study to evaluate the efficacy,
pharmacokinetics, safety, and immunogenicity
of subcutaneously administered ustekinumab
or guselkumab in pediatric participants with
active juvenile psoriatic arthritis.
III

Ongoing*

11/2022

Bulgaria

Czech Republic

Hungary

Spain

PSA
Evaluation of sonelokimab in patients with
active psoriatic arthritis.
II

Ongoing*

10/2022

Germany

Psoriasis
Efficacy and safety of deucravacitinib versus
placebo in participants with moderate-to-
severe scalp psoriasis.
IV

Ongoing*

10/2022

Hungary

Psoriasis
Comparison of the efficacy and safety between two
study drugs in skin disease patients.
III

Ongoing*

10/2022

Poland

PSA
A phase 2a, randomized, double-blind, placebo-
controlled study to investigate the efficacy, safety,
tolerability, pharmacokinetics, and
pharmacodynamics of zunsemetinib vs placebo in
patients with moderate-to-severe active psoriatic
arthritis.
II

Ongoing*

09/2022

Estonia

Psoriasis
A study to compare pharmacokinetics, efficacy, and
safety of ct-p17 with humira in patients with
moderate to severe chronic plaque psoriasis.
III

Ongoing*

08/2022

Bulgaria

Czech Republic

Estonia

Poland

Psoriasis
Hulio interchangeability to humira, comparing
pharmacokinetics, efficacy, safety and
immunogenicity.
III

Ongoing*

07/2022
Estonia
Latvia
Psoriasis
Bmab 1200 versus stelara in patients with moderate
to severe chronic plaque psoriasis.
III

Ongoing*

07/2022

Spain

Psoriasis
A study to evaluate the efficacy, safety, and
tolerability of an oral tablet formulation of jnj-
77242113 for the treatment of moderate-to-severe
plaque psoriasis.
II

Ongoing*

06/2022

Germany

Poland

Spain

Psoriasis
A long-term extension study of jnj-77242113 in
participants with moderate-to-severe plaque
psoriasis.
II

Ongoing*

03/2022

Italy

PSA
Identification of synovial biomarkers of response to
ixekizumab in refractory psoriatic arthritis.
IV

Ongoing*

03/2022

Spain

Psoriasis
A study to investigate the safety and efficacy of
multiple doses of jnj-77242113 in participants with
moderate to severe plaque psoriasis.
II

Ongoing*

Date

Country

10/2023

Germany

Disease

Title

PSA

a Prospective, Randomized, Controlled, Open Label, Assessor-Blinded, Parallel-Group Phase III Clinical Trial to Evaluate the Impact of Tapering Systemic Immunosuppressive Therapy
in a Treat-to-Target Approach on Maintaining Minimal Disease Activity in Adult Subjects with
Psoriatic Arthritis.

Phase

Status

+info

III/IV

Ongoing*

Date

Country

06/2023

Germany

Disease

Title

Both

Safety and immunologic response of shingrix vaccination in patients suffering from psoriasis or psoriatic arthritis shivap.

Phase

Status

+info

II

Ongoing*

Date

Country

04/2023

Denmark

Disease

Title

Psoriasis

An Investigator-Initiated, Phase 4, Open-Label, Single-Arm, Single-Center Study Investigating the Tissue-Resident Memory t-Cells and Disease Memory in Psoriasis Skin During Guselkumab Treatment. The Gusmem Study.

Phase

Status

+info

IV

Ongoing*

Date

Country

03/2023

Bulgaria

Czech Republic

Germany

Hungary

Spain

Disease

Title

PSA

Vtx958 versus placebo for the treatment of active psoriatic arthritis.

Phase

Status

+info

II

Ongoing*

Date

Country

03/2023

Poland

Disease

Title

Psoriasis

A research study to evaluate if vtx958, a test medicine, not yet approved for doctors to prescribe, is safe and will help in the treatment of psoriasis.

Phase

Status

+info

II

Ongoing*

Date

Country

01/2023

Czech Republic

Poland

Disease

Title

Psoriasis

A study to evaluate esk-001 in patients with psoriasis.

Phase

Status

+info

II

Ongoing*

Date

Country

01/2023

France

Greece

Italy

Spain

Disease

Title

PSA

Apremilast study in children with active oral ulcers associated with behets disease or juvenile psoriatic arthritis.

Phase

Status

+info

III

Ongoing*

Date

Country

11/2022

Denmark

France

Germany

Netherlands

Poland

Spain

Disease

Title

PSA

Study to evaluate the efficacy, pharmacokinetics, safety, and immunogenicity of subcutaneously administered ustekinumab or guselkumab in pediatric participants with active juvenile psoriatic arthritis.

Phase

Status

+info

III

Ongoing*

Date

Country

11/2022

Bulgaria

Czech Republic

Hungary

Spain

Disease

Title

PSA

Evaluation of sonelokimab in patients with active psoriatic arthritis.

Phase

Status

+info

II

Ongoing*

Date

Country

10/2022

Germany

Disease

Title

Psoriasis

Efficacy and safety of deucravacitinib versus placebo in participants with moderate-to-severe scalp psoriasis.

Phase

Status

+info

IV

Ongoing*

Date

Country

10/2022

Hungary

Disease

Title

Psoriasis

Comparison of the efficacy and safety between two study drugs in skin disease patients.

Phase

Status

+info

III

Ongoing*

Date

Country

10/2022

Poland

Disease

Title

PSA

A phase 2a, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of zunsemetinib vs placebo in
patients with moderate-to-severe active psoriatic arthritis.

Phase

Status

+info

II

Ongoing*

Date

Country

09/2022

Estonia

Disease

Title

Psoriasis

A study to compare pharmacokinetics, efficacy, and safety of ct-p17 with humira in patients with moderate to severe chronic plaque psoriasis.

Phase

Status

+info

III

Ongoing*

Date

Country

08/2022

Bulgaria

Czech Republic

Estonia

Poland

Disease

Title

Psoriasis

Hulio interchangeability to humira, comparing pharmacokinetics, efficacy, safety and immunogenicity.

Phase

Status

+info

III

Ongoing*

Date

Country

07/2022

Estonia

Latvia

Disease

Title

Psoriasis

Bmab 1200 versus stelara in patients with moderate
to severe chronic plaque psoriasis.

Phase

Status

+info

III

Ongoing*

Date

Country

07/2022

Spain

Disease

Title